GENETIC ANALYSIS NK -60 Financial Flexibility Index
GENETIC ANALYSIS NK -60 financial flexibility index. GENETIC ANALYSIS NK -60 (8V8) has a Financial Flexibility Index of -0.13x as of June 2026. Free cash flow of €-3.22 Million (operating CF €-4.52 Million minus capex €1.30 Million) represents 0% of total liabilities (€23.93 Million). See 8V8 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of GENETIC ANALYSIS NK -60 (2021–2025)
Financial flexibility index of GENETIC ANALYSIS NK -60 from 2021 to 2025. Historical Financial Flexibility Index trend for GENETIC ANALYSIS NK -60 across 5 annual periods. Explore 8V8 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
GENETIC ANALYSIS NK -60 Financial Flexibility Index by Year (2021–2025)
GENETIC ANALYSIS NK -60 financial flexibility index by year from 2021 to 2025. Year-by-year free cash flow to debt coverage for GENETIC ANALYSIS NK -60. For the full cash flow conversion analysis, see 8V8 cash flow metrics.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.31x | €7.94 Million | €2.40 Million | €25.37 Million | ▲ +164.3% |
| 2024 | -0.49x | €-9.68 Million | €-11.62 Million | €19.88 Million | ▲ +37.0% |
| 2023 | -0.77x | €-16.59 Million | €-17.23 Million | €21.49 Million | ▲ +18.6% |
| 2022 | -0.95x | €-19.23 Million | €-19.46 Million | €20.28 Million | ▲ +57.9% |
| 2021 | -2.25x | €-25.66 Million | €-27.62 Million | €11.40 Million | — |